NEW YORK – MGI Tech said Tuesday that it has collaborated with OncoDNA to make the firm's OncoDeep cancer sequencing kits compatible with MGI's DNBSeq sequencers.
Under the terms of the deal, the firms will comarket each other's products. An MGI spokesperson said the workflow will require a conversion product, which MGI is selling.
Financial and other terms of the collaboration were not disclosed.
"We are not only expanding the technological options available to laboratories but also enhancing the quality and accuracy of genomic profiling in clinical practice," OncoDNA Founder Jean-Pol Detiffe said in a statement. "This collaboration underscores our commitment to providing cutting-edge solutions that meet the evolving needs of cancer care."
An OncoDNA spokesperson said the firm has already closed several deals that combine MGI's sequencing tech and the OncoDeep assay.
Belgium-based OncoDNA was founded in 2012. In 2022, the firm launched a kitted version of its OncoDeep assay, which sequences DNA and RNA, covering 638 cancer-related genes.